Ogkologos

4396 ΔΗΜΟΣΙΕΥΣΕΙΣ 0 ΣΧΟΛΙΑ

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for...

Ogkologos - 8 Ιουλίου, 2025

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS...

Ogkologos - 7 Ιουλίου, 2025

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO...

Ogkologos - 4 Ιουλίου, 2025

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step...

Ogkologos - 4 Ιουλίου, 2025

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

Ogkologos - 4 Ιουλίου, 2025

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

Ogkologos - 3 Ιουλίου, 2025

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive...

Ogkologos - 2 Ιουλίου, 2025

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of...

Ogkologos - 1 Ιουλίου, 2025

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with...

Ogkologos - 1 Ιουλίου, 2025

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

Ogkologos - 30 Ιουνίου, 2025

1...454647...440 Σελίδα 46 από 440

MOST POPULAR

LGBTQ+ Voices: Listening to Sexual and Gender Minority People Affected by...

1 Μαΐου, 2024

A Large Genomic Analysis Identifies That Persistent Tumour Mutational Burden Is...

6 Φεβρουαρίου, 2023

10 Ways You Can Nurture A More Sustainable Garden

18 Ιουνίου, 2021

Molecular Profiling Identifies Targetable Alterations in Majority of Patients with Advanced...

9 Αυγούστου, 2022

Φόρτωση περισσοτέρων

Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for...

Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS...

ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO...

ESMO Welcomes the European Commission’s Life Sciences Strategy: A Vital Step...

FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer

EMA Recommends Granting a Marketing Authorisation for Nirogacestat

Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive...

ESMO Calls for Oncology-Specific Safeguards in EU Joint Clinical Assessments of...

Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with...

Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer

MOST POPULAR

LGBTQ+ Voices: Listening to Sexual and Gender Minority People Affected by...

A Large Genomic Analysis Identifies That Persistent Tumour Mutational Burden Is...

10 Ways You Can Nurture A More Sustainable Garden

Molecular Profiling Identifies Targetable Alterations in Majority of Patients with Advanced...

HOT NEWS

Παρακολούθηση και Φροντίδα

Targeted Therapy for Treating Advanced Gastrointestinal Stromal Tumors (GISTs): The ASCO...

Giving Birth Before Age 20 Cuts Breast Risk By 50%, And...

El cáncer en mi comunidad: Cómo superar las desigualdades en la...

ΔΗΜΟΦΙΛΕΊΣ ΘΈΣΕΙΣ

ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ)

ΣΤΑΤΙΣΤΙΚΑ

ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ

ΔΗΜΟΦΙΛΗ ΚΑΤΗΓΟΡΙΑ